News
Tirzepatide 15 mg: 1.60 kg of Fat-Free Mass Lost
Tirzepatide 15 mg cut fat-free mass by 1.60 kg in a meta-analysis of 19 trials, where laboratory screening found risk the trial reports missed.
GHK-Cu: 50 Years of Research, None on Injection
GHK-Cu has decades of human trials as a topical serum and none as an injection, NPR reports, with an FDA panel reviewing the injectable in February.
Tirzepatide and Semaglutide: 15-20% in a New Review
Tirzepatide and semaglutide give 15 to 20 percent mean weight loss over 12 to 18 months, a new narrative review reports, with wider gains.
Peptides and Cancer: What Memorial Sloan Kettering Says
Peptides sold online for wellness have not been through clinical trials, and Memorial Sloan Kettering has now told patients why that matters.
Tirzepatide in Prader-Willi: 3 Measures After One Swap
Tirzepatide replaced a GLP-1 agonist in a woman with Prader-Willi syndrome and refractory diabetes, and appetite, weight and glucose all improved.
GLP-1 in Resistant Hypertension: Equal BP, 4,153 Pairs
GLP-1 agonists and mineralocorticoid antagonists cut blood pressure almost equally in 4,153 matched pairs, yet the hard outcomes separated sharply.
Tirzepatide and Metformin: When Glucose Masks Ketoacidosis
Tirzepatide with metformin preceded severe lactic acidosis and ketoacidosis at near-normal glucose in a 59-year-old woman, who recovered on dialysis.
GLP-1: WHO Guidelines, 1 Billion People, 3 Industries
GLP-1 now has a WHO guideline, and a Science editorial names the three industries competing around it: pharmaceutical, food and wellness.
Semaglutide vs Pair-Fed Rats: Splitting Drug From Weight
Semaglutide and pair-fed rats both gained on reproductive measures, but the hormone results separated the drug effect from the weight loss effect.
Semaglutide Extended Lifespan in Mice Treated at 20 Months
Semaglutide started at 20 months extended lifespan in female mice and beat matched calorie restriction on memory, exploration and glucose control.